NEW
Stock Screener with Intrinsic Value
Summit Therapeutics Inc. (SMMT)
Last Price$19.04.6%
Market Cap$13.8B
Intrinsic value score
7/10
Great
Intrinsic value
$0.6
DCF value - N/A
Relative value - $0.6
Overvalued
96.7%
LTM P/E
(70.3x)
Peer set median 5.1x
Discount rate
7.8%
SMMT Intrinsic value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
SMMT Historical Intrinsic Value
Crunching data... Almost there!
SMMT vs Peer Set: Intrinsic Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for SMMT
DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Summit Therapeutics Inc. intrinsic value?
As of Jan 17, 2025, Summit Therapeutics Inc. Intrinsic Value is $0.6. This suggests it may be overvalued by 96.7% compared to its current price of around $19.0.
What is Summit Therapeutics Inc. DCF (discounted cash flow) valuation?
As of Jan 17, 2025, Summit Therapeutics Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $19.0, using a discount rate of 7.8% and terminal growth rate of 3.0%.
Is Summit Therapeutics Inc. overvalued or undervalued?
Summit Therapeutics Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $0.6, compared to a market price of around $19.0. This suggests a potential overvaluation of 96.7%.